Malignant Ovarian Neoplasm — Trials

Malignant Ovarian Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 684
Recruiting: 385
Ph III recruiting: 46
Growth YoY: +9.8%
Industry share: 37%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.8%
Trials / 1,000 deaths: 53.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (437)

clinicaltrialsPublishedShowing 1–50 of 160 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05877599	A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation	recruiting	Phase 1	45	AstraZenecaINDUSTRY	1	Sep 29, 2026	clinicaltrials
NCT06799065	First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer	recruiting	Phase 1 / Phase 2	218	Accent TherapeuticsINDUSTRY	1	Sep 29, 2026